Key terms
About ANTX
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ANTX news
Apr 08
3:55am ET
Maintaining Caution: AN2 Therapeutics Hold Rating Amidst Epetraborole Trial Uncertainties
Apr 02
4:35am ET
AN2 Therapeutics upgraded to Outperform from Market Perform at JMP Securities
Apr 02
12:35am ET
Buy Rating Affirmed for AN2 Therapeutics Amidst Upcoming Catalysts and Strong Valuation Prospects
Mar 31
2:02am ET
AN2 Therapeutics’ High-Stakes Gamble: Navigating FDA Approval for Epetraborole Amid Clinical Trial Uncertainties
Mar 28
4:12pm ET
AN2 Therapeutics reports Q4 EPS (57c), consensus (75c)
Mar 05
10:25am ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Mar 05
4:55am ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Mar 01
12:19pm ET
Cantor Fitzgerald biotech/biopharma analysts analyst/industry conference call
Feb 28
4:35pm ET
SHAREHOLDER ALERT: Potential Recovery for AN2 Therapeutics, Inc. (ANTX) Investors
Feb 12
7:14pm ET
AN2 Therapeutics downgraded to Market Perform from Outperform at Leerink
Feb 12
11:44am ET
AN2 Therapeutics downgraded to In Line from Outperform at Evercore ISI
Feb 12
10:54am ET
AN2 Therapeutics downgraded to Perform from Outperform at Oppenheimer
Feb 12
10:50am ET
AN2 Therapeutics downgraded to Market Perform from Outperform at JMP Securities
Feb 12
9:55am ET
AN2 Therapeutics, Inc. (ANTX) was downgraded to a Hold Rating at JMP Securities
Feb 12
8:25am ET
AN2 Therapeutics Reassesses Phase 3 Trial Amid Efficacy Concerns
Feb 12
8:12am ET
AN2 Therapeutics Reviews Epetraborole Phase 3 Trial Enrollment
Feb 12
8:09am ET
AN2 Therapeutics Reviews Phase 2 Data, Pauses Phase 3 Trial Enrollment
Feb 12
6:47am ET
AN2 Therapeutics pausing enrollment in Phase 2 trial of epetraborole
No recent press releases are available for ANTX
ANTX Financials
Key terms
Ad Feedback
ANTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ANTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range